Thrombosis in hemophiliacs is a very unusual event mostly reported in patients treated with concentrates containing large quantities of activated coagulation factors. A patient with hemophilia A is reported who had an acute myocardial infarction and in whom investigation for hereditary thrombophilia showed a prothrombotic molecular defect, the G20210A prothrombin mutation.
We report a 52-year-old man, known to have a moderate haemophilia A (FVIII.C level 0.04 U/mL). In the previous 10 years he had two hemorragic episodes (muscle hematomas). Because of a hepatitis C-related chronic hepatitis, he received alpha-2b interferon and then alpha-2b interferon and ribavirin, without significant biochemical and virologic responses. For more than 5 years, there was a history of essential hypertension treated with antihypertensive drugs. He was admitted in the coronary care unit due to chest pain accompanied by weakness. A diagnosis of acute anteroseptal myocardial infarction was made and an antithrombotic treatment with a low dose of low-molecular-weight heparin (nadroparin 3800 U per day) and then with aspirin was started. After 3 days, the patient was discharged. A study for hereditary thrombophilia was performed. Antithrombin III, protein C, and protein S were normal. The investigation for the Factor V Leiden mutation and G20210A prothrombin gene mutation was made by assays based on the reverse-hybridization principle, including three successive steps: isolation of DNA from peripheral blood, in vitro amplification of gene sequences, hybridization of the amplification products with allele-specific oligonucleotides probes (Vienna Lab, Labordiagnostika GmbH). The G20210A prothrombin mutation in heterozygous form was demonstrated. Then a coronary arteriography showed an obstructive lesion within the proximal tract of the anterior interventricular artery, treated with stent placement. After 1 year the patient is well.
Thrombotic complications in hemophilia generally have been associated with infusion of intermediate-purity FIX concentrates containing activated coagulation factors. Also prothrombin complex concentrates have a thrombogenic potential. Thrombosis was more common in patients treated with large doses and with concomitant risk factors, such as surgery, prolonged immobilization, or underlying cardiovascular disease (1) . Recently acute myocardial infarction has been reported in a patient with hemophilia and inhibitor after administration of recombinant activated factor VII (2). Apart from these situations, some reports suggest that hemophilia does not seem protective from coronary artery disease. Myocardial infarction not related to hemostatic 359 Thrombosis in Hemophiliacs with Prothrombotic Molecular Defect treatments has been reported in hemophiliacs and in some cases cardiac catheterization showed extensive coronary atherosclerosis (3, 4) . In recent years, two prothrombotic molecular defects with high prevalence in the general population have been described: Factor V Leiden mutation and G20210A prothrombin gene mutation. It has been suggested that the co-inheritance of severe hemophilia A with these molecular defects influences the clinical phenotype of the bleeding disorder, reducing the bleeding episodes, or delaying the symptomatic hemorrhagic onset (5) (6) (7) . In addition, thrombotic events have been described in hemophiliac patients in whom the Factor V Leiden was showed. A venous thromboembolism developed after hip fracture surgery in one patient, while a boy presented a cerebral infarct in the absence of risk factors (8, 9) . Our patient presented with an arterial thrombotic complication; in his history there was the hypertension as major cardiovascular risk factor and the investigation for hereditary thrombophilia has shown the G20210A mutation of prothrombin gene in heterozygous form. Whereas Factor V Leiden and 20210 G-to-A mutation are well-documented genetic risk determinants for venous thromboembolic disease, their role in arterial thrombosis is still controversial (10) . It remains a matter of debate whether the G20210A prothrombin mutation is a risk factor for coronary heart disease. In their study, Rosendaal and colleagues concluded that the prothrombin mutation increases the risk of myocardial infarction in young women (11) ; from the study of Gardemann and colleagues emerges the hypothesis that the importance of the prothrombin mutation for coronary heart disease may be restricted to individuals with major cardiovascular risk factors (12) . Even Burzotta and colleagues suggest that the G20210A prothrombin mutation may be a pathogenetic factor for coronary heart disease in patients with limited atherosclerotic involvement (13) . The single case reported here absolutely does not allow hypotheses regarding a relation between the ischemic event of our patient and the prothrombotic genetic polymorphism. Rather we emphasize the coexistence in the same subject of a hereditary bleeding defect and of a prothrombotic mutation. Our experience suggests that hemophilia does not seem to have a protective effect from coronary artery disease.
